Rodman & Renshaw started coverage on shares of Agenus (NASDAQ:AGEN – Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $19.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s target price points to a potential upside of 92.11% from the stock’s current price.
A number of other analysts also recently issued reports on the company. Weiss Ratings downgraded Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. B. Riley Financial reissued a “buy” rating and issued a $14.00 target price (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Wall Street Zen cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Chardan Capital began coverage on shares of Agenus in a research report on Friday, September 18th. They set a “buy” rating and a $40.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 target price (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.50.
Get Our Latest Stock Report on Agenus
Agenus Price Performance
Agenus (NASDAQ:AGEN – Get Free Report) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. As a group, equities analysts expect that Agenus will post -0.3 EPS for the current year.
Institutional Trading of Agenus
Several institutional investors and hedge funds have recently modified their holdings of the stock. Globeflex Capital L P bought a new position in Agenus in the second quarter worth approximately $1,281,000. Bank of New York Mellon Corp bought a new stake in Agenus during the 2nd quarter valued at $311,000. Bank of America Corp DE raised its position in Agenus by 796.7% during the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 105,536 shares in the last quarter. Ovata Capital Management Ltd purchased a new stake in shares of Agenus in the 4th quarter worth $97,000. Finally, Redwood Family Wealth LLC purchased a new stake in shares of Agenus in the 4th quarter worth $44,000. Institutional investors own 61.46% of the company’s stock.
About Agenus
Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.
The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies.
See Also
- Five stocks we like better than Agenus
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
